GBT Global Blood Therapeutics Inc.

28.50
+1.35  (5%)
Previous Close 27.15
Open 27.25
Price To book 4.42
Market Cap 1244788914
Shares 43,676,804
Volume 923,833
Short Ratio 8.78
Av. Daily Volume 704,219

SEC filingsSee all SEC filings

  1. 8-K - Current report 171070222
  2. 8-K - Current report 171068924
  3. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 171047214
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011635
  5. 8-K - Current report 171011523

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a initiated November 2016. Data due 4Q 2017.
GBT440
Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest
Announced January 18, 2017 that Phase 3 enrollment has commenced. Previous guidance is for top-line data due 1H 2019.
GBT440 - HOPE
Sickle cell disease in adults
Phase 2a initiated June 2016. Data due 2017
GBT440
Idiopathic pulmonary fibrosis (IPF)
Phase 2a initiated June 2016. Preliminary data released at European Hematology Association (EHA) - June 23, 2017. Noted July 10, 2017 that trial has been expanded to include a new single-dose cohort in children age 6 to 11 with data due by the end of 2017.
GBT440 HOPE-KIDS 1
Sickle cell disease - children age 6-17.

Latest News

  1. One Thing To Consider Before Buying Global Blood Therapeutics Inc (GBT)
  2. Global Blood Therapeutic Sees IBD RS Rating Climb To 71
  3. Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference
  4. Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD)
  5. Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September
  6. Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference
  7. Global Blood reports 2Q loss
  8. Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results
  9. Global Blood Therapeutics Announces New Employment Inducement Grants
  10. Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population
  11. Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
  12. Global Blood Shares Pop on Priority Designation; Kite Pharma Rises on Patent News: Biotech Movers
  13. Global Blood Therapeutics stock surges 5% on eligibility for European priority drug program
  14. Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)
  15. 5 Top Performing Stocks of the Best ETF of Q1

SEC Filings

  1. 8-K - Current report 171070222
  2. 8-K - Current report 171068924
  3. S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers 171047214
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171011635
  5. 8-K - Current report 171011523
  6. 8-K - Current report 17997217
  7. 8-K - Current report 17956385
  8. 8-K - Current report 17935254
  9. 8-K - Current report 17927618
  10. 8-K - Current report 17925122